Enterprise demand for sovereign AI favors Palantir's transformation model. In a two-pronged AI economy, businesses can retain their IP and use low-cost open models while frontier labs compete for the last increment of intelligence. x.com 

AI-enabled drug discovery is the next re-rate, because if AI raises lab hit rates, the cost of failure falls across the sector and beaten-down platforms re-rate first. Recursion is the cleanest expression, an AI-first platform built to industrialize discovery. AbCellera and Tempus apply AI to antibody discovery and the diagnostics data layer, with real revenue under the story. The trap is paying a winner's multiple before the trial proves the winner. x.com 

Palantir's reliance on pay-as-you-go service with refunds makes customer cancellations and sudden earnings declines or write-downs a serious risk as AI and high SaaS prices pressure the business. Its 10-Q warns of these risks. Anthropic can and will easily replace Palantir with an all-in-one platform under Democratic control of the legislative branches. x.com  x.com 

These 12 stocks offer exposure to AI, automation, health care, consumer growth and nuclear demand. AMD makes AI chips; Oracle builds AI cloud; Vertex has multiple drug opportunities. Arista supplies data-center switches, KLA inspection tools and Cadence chip-design tools. Palantir sells AI platforms; Symbotic automates warehouses; Alphabet spans search, cloud and AI. Celsius has US consumer momentum, AppLovin runs high-margin mobile ads, and Cameco mines uranium and co-owns Westinghouse. x.com  … Show more

Palantir defines what AI agents should do and redesigns workflows, while most others build gates because they cannot define the agents' tasks. That makes Palantir the best security stock; proving it can make agents work properly could drive a rerating. x.com  x.com  x.com 

Palantir's valuation premium is shrinking because it is no longer the only player in defense AI. Its 2024-25 run at hundreds of times earnings rested on being first and only there, but frontier labs it once partnered with now sign directly with the Pentagon, and OpenAI and Anthropic are moving into forward-deployed engineering for enterprises. CEO Alex Karp's attack on the labs reflects that pressure. Opportunity returns once revenue and profit scale up and the valuation is digested. x.com 

The AI and biology basket now adds AbCellera and Hims & Hers and looks set to destroy the market over the next 10 years. ImmunityBio is the immune system's operating system, Nautilus is the Tesla of proteomics, Recursion is superhuman biology-chemistry AI, AbCellera is the machine that can hit any target in the body, and Hims & Hers is the dominant direct-to-consumer distribution layer. x.com 

Better underwriting at Root, AI data demand at Innodata, defense breadth at Applied Aerospace & Defense, scaled voice AI at SoundHound, more organ access via TransMedics, profitable insurance at Lemonade, autonomous defense at Ondas and successful medicines at AbCellera could drive outsized growth. These eight smaller companies have a realistic path to 5x+ over 5-10 years if they execute on those opportunities. x.com  x.com  x.com  x.com  x.com  x.com  x.com  x.com 

Palantir's multiple is too high to pay, so the stock is likely to be a source of funds for two-plus years. That holds even if @DivesTech is right that the narrative of Anthropic eating Palantir's lunch is wrong and Palantir sits at the epicenter of AI leaders. x.com 

Palantir looks very bullish after a strong week driven by new deals. It named Nebius its preferred sovereign AI infrastructure partner, raised full-year revenue guidance, and expanded AIP contracts across healthcare, defense and manufacturing. x.com  x.com